checkAd

     101  0 Kommentare Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2024 Financial Results

    Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2024 financial results on Wednesday, May 29, 2024, before markets open. A conference call and webcast to discuss the financial results will be held on Wednesday, May 29, 2024, at 8:15am ET.

    To view, listen to, and participate in the live webcast, please follow the link below:

    https://events.q4inc.com/attendee/221238520

    To listen and participate via the conference call, please dial:

    North American Toll-Free: 1-800-549-8228
    Local (Toronto): 1-289-819-1520
    Local (New York): 1-646-564-2877
    Conference ID: 29401

    Participants will be able to ask questions of Company management during the Q&A portion of the conference call either by asking them on the call or by submitting them using the chat function on the webcast.

    A recording of the call will be available on www.covalon.com under News & Events on the Investors tab.

    Lesen Sie auch

    Copies of Covalon’s financial statements and MD&A can be obtained on SEDAR PLUS at www.sedarplus.ca and under SEDAR Filings on the Investors tab of Covalon’s website.

    Those interested in learning more about Covalon’s solutions can visit www.covalon.com or follow Covalon on LinkedIn, Facebook, or Instagram.

    About Covalon
    Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions for advanced wound care, infection control, and medical device coatings. Through a strong portfolio of patented technologies and solutions, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.


    The Covalon Technologies Stock at the time of publication of the news with a raise of 0,00 % to 1,040CAD on TSX Venture stock exchange (21. Mai 2024, 17:22 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2024 Financial Results Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2024 financial results on Wednesday, May 29, 2024, before markets open. A conference call and …